Victrelis

Quote
I'm right there with you. My Merck rep is a douchebag and can't believe the loser is still around! Now I have to go help him after all these years? This just gives him more of a reason to stay home and doing nothing! Schering and now Merck reps have NEVER been good to work with! And based on their share, offices don't care for them either. I'm just waiting to hear these losers talk about this venture! So Merck, what do you have to say?????
 












Merck Enlists Roche's Help To Promote New Hepatitis Drug - Headline from the Wall Street Journal. Congrats Merck Reps. You must be so proud we Genetech reps have to come in and do your job for you.
 






The jealousy from the vertex reps whose company couldn't close their own deal is a joke. And yes it's obvious this is from vertex reps cause this deal isn't just about sales of Victrelis. It's much much more.

Many companies co promote and i look fwd to working with my Genentech counterpart. We respect each other and will have a great working relationship because we are professionals not children.
 






While Merck maybe be spinning the positive long term benefits of this arrangement, don't let your arrogance blind you to the fact we are being called upon to do your job. We have dominated in the interferon market. While it's great you play nice with your rep, don't expect the rest of the field force to be excited about making education calls on your behalf to move your product we when are already blowing out Pegasys. It also doesn't change the fact Vertex has a better product. That's reality not jealousy.
 






The better product is the one that has the safety and efficacy. Is shorter treatment worth it when there is rash, anemia and discontiuation rates that are high. Then I guess pushing a treatment that doesn't work for the majority of patients is why Genentech chose to copromote with the better drug. All the studies with Telaprevir were done with Pegasys and Genetech chose Merck because Victrelis is a better drug in the long run for patients- they make it through treatment and they don't have rash clinics.
 






so answer me a question:

telap is considered a better drug. Why? Top line SVR was 79% and SOC was 46%. That's a 1.71 fold improvement over SOC

Bocep top line SVR is 66% with SOC at 38%. That's a 1.73 fold improvement over SOC.

why is telap better?
 






Anonymous said:
While Merck maybe be spinning the positive long term benefits of this arrangement, don't let your arrogance blind you to the fact we are being called upon to do your job. We have dominated in the interferon market. While it's great you play nice with your rep, don't expect the rest of the field force to be excited about making education calls on your behalf to move your product we when are already blowing out Pegasys. It also doesn't change the fact Vertex has a better product. That's reality not jealousy.
Click to expand...

so if Vertex would have signed an agreement with Genentech for the same thing would you be on the Vertex board posting the same crud?

BTW, I truly hope you don't detail bocep, your unaided recall comes back crappy and you miss out on 30% of your bonus.
 


















Anonymous said:
so answer me a question:

telap is considered a better drug. Why? Top line SVR was 79% and SOC was 46%. That's a 1.71 fold improvement over SOC

Bocep top line SVR is 66% with SOC at 38%. That's a 1.73 fold improvement over SOC.

why is telap better?
Click to expand...

Too easy! because in Victrelis study- "SOC" was not SOC- it was PegIntron. That's like saying your a "10" when you're in a beauty contest with Rosie ODonnell.
 






Merck knows that the Peg Intron future is not as bright as the boceprevir future. The next generation of therapies will look to minimize exposure to ribavirin and interferon. They choose to try to win in the short term at tela versus bocep at the price of Intron. It is about ganging up on Vertex. Roche is in this deal probably because they only have Pegasys in the game at the present and might have been spurned by Vertex. And which therapy will consume more Pegasys? The short telaprevir or the the longer boceprevir? If Merck does not show good Victrelis numbers, the stock price will take a hit; Nobody will look too hard at the PegIntron numbers - the total is unlikely to go down even as the market share might. The best specialists will go with the combo that showed the best results for cure (Pegasys plus telaprevir). The majority of the prescribers will follow the path that has dictated their prescribing patterns historically. Hype, money, and pressure will move sales with that lot.
 






Anonymous said:
so answer me a question:

telap is considered a better drug. Why? Top line SVR was 79% and SOC was 46%. That's a 1.71 fold improvement over SOC

Bocep top line SVR is 66% with SOC at 38%. That's a 1.73 fold improvement over SOC.

why is telap better?
Click to expand...

This is a PERFECT example of why Roche/Genentech continues to kick your ass! "So Dr., I'm here to promote the new PI. And just to let you know, our delta difference is .02 percent better than Vertex. Now isn't that important to tell your patients? Never mind that 79% SVR is the highest in the marketplace, our delta is greater! And yes, we used PegIntron as our peg of choice because it has less than a 20% market share!"

PLEASE GOD....I can't work with these douchebags!!!!!!
 






Anonymous said:
The jealousy from the vertex reps whose company couldn't close their own deal is a joke. And yes it's obvious this is from vertex reps cause this deal isn't just about sales of Victrelis. It's much much more.

Many companies co promote and i look fwd to working with my Genentech counterpart. We respect each other and will have a great working relationship because we are professionals not children.
Click to expand...

Genentech here...This is pretty funny....must be Merck upper sales management because this is NOT what we are hearing from your salesforce or ours. And face it, the reason we're "working" with you has nothing to do with the drug...it has to do with the $25 million + you are paying us! Boy, I bet the Merck reps wish that that money was going into their incentive plan....sorry Merckies....it's coming to us.
 












Vertex and Merck will both come out on top in this one. It is largely a new business with warehoused patients. The rumored price of therapy is so high that gross margins will be 85% or greater. Insurance companies and the state/fed governments will pick up the tab. Question will be how much gets spent or how much price gets discounted in order to win the war.
 






I do love how one disgruntled, miserable person posts several times to try to make us believe that the entire Roche field force is so up in arms about this deal. I, for one, don't buy it.
 






miserable, bitter people. I feel for your families and loved ones. In a few months we'll see where market share falls, until then the bile will flow all over this board. Very very sad.
 












Anonymous said:
I do love how one disgruntled, miserable person posts several times to try to make us believe that the entire Roche field force is so up in arms about this deal. I, for one, don't buy it.
Click to expand...

Ask your Genetech rep if you don't believe it. While we are forced to provide docs with Victrelis information, we are still competing with you on Peg sales. Or more accurately, you are competing with us. We get to help you while your contracting team continues to to go after our managed contracts. Sorry we're not as giddy as you think we should be.
 






Top Bottom
Back
Quote